161 related articles for article (PubMed ID: 35510091)
61. Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016.
Mollard S; Lurienne L; Heimann SM; Bandinelli PA
J Hosp Infect; 2019 Jun; 102(2):135-140. PubMed ID: 30690052
[TBL] [Abstract][Full Text] [Related]
62. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
[TBL] [Abstract][Full Text] [Related]
63. Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review.
Armstrong EP; Malone DC; Franic DM; Pham SV; Gratie D; Amin A
Infect Dis Ther; 2023 Jul; 12(7):1775-1795. PubMed ID: 37395984
[TBL] [Abstract][Full Text] [Related]
64. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Rodrigues R; Barber GE; Ananthakrishnan AN
Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
[TBL] [Abstract][Full Text] [Related]
65. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
66. An analysis of the outcomes of Clostridioides difficile occurring in intestinal transplant recipients requiring hospitalization.
Amjad W; Schiano T; Segovia MC; Malik A; Weiner J; Horslen S; Jafri SM
Transpl Infect Dis; 2023 Feb; 25(1):e13951. PubMed ID: 36621893
[TBL] [Abstract][Full Text] [Related]
67. Fecal Microbiota Transplantation and Medical Therapy for Clostridium difficile Infection : Meta-analysis of Randomized Controlled Trials.
Singh T; Bedi P; Bumrah K; Gandhi D; Arora T; Verma N; Schleicher M; Rai MP; Garg R; Verma B; Sanaka MR
J Clin Gastroenterol; 2022 Nov-Dec 01; 56(10):881-888. PubMed ID: 34516460
[TBL] [Abstract][Full Text] [Related]
68. Clostridioides difficile infection in US hospitals: a national inpatient sample study.
Ramai D; Dang-Ho KP; Lewis C; Fields PJ; Ofosu A; Barakat M; Aamar A; Ofori E; Lai J; Lanke G; Dhaliwal A; Reddy M; Gasperino J
Int J Colorectal Dis; 2020 Oct; 35(10):1929-1935. PubMed ID: 32556651
[TBL] [Abstract][Full Text] [Related]
69. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life.
Hengel RL; Schroeder CP; Jo J; Ritter TE; Nathan RV; Gonzales-Luna AJ; Obi EN; Dillon RJ; Van Anglen LJ; Garey KW
J Patient Rep Outcomes; 2022 May; 6(1):49. PubMed ID: 35567724
[TBL] [Abstract][Full Text] [Related]
70. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent
Šamadan L; Jeličić M; Vince A; Papić N
Antibiotics (Basel); 2021 Jun; 10(7):. PubMed ID: 34198964
[TBL] [Abstract][Full Text] [Related]
71. Outcomes of
Gayam V; Mandal AK; Ditah CM; Sidhu J; Konala VM; Adapa S; Naramala S; Garlapati P
South Med J; 2020 Nov; 113(11):593-599. PubMed ID: 33140114
[TBL] [Abstract][Full Text] [Related]
72. The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases.
Olsen MA; Young-Xu Y; Stwalley D; Kelly CP; Gerding DN; Saeed MJ; Mahé C; Dubberke ER
BMC Infect Dis; 2016 Apr; 16():177. PubMed ID: 27102582
[TBL] [Abstract][Full Text] [Related]
73. Effect of Clostridium difficile Prevalence in Hospitals and Nursing Homes on Risk of Infection.
Joyce NR; Mylonakis E; Mor V
J Am Geriatr Soc; 2017 Jul; 65(7):1527-1534. PubMed ID: 28394408
[TBL] [Abstract][Full Text] [Related]
74. Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries.
Yu H; Flaster N; Casanello AL; Curcio D
Braz J Infect Dis; 2021; 25(1):101040. PubMed ID: 33290727
[TBL] [Abstract][Full Text] [Related]
75. Development and validation of a recurrent Clostridium difficile risk-prediction model.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
J Hosp Med; 2014 Jul; 9(7):418-23. PubMed ID: 24700708
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
[TBL] [Abstract][Full Text] [Related]
77. Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States.
Shorr AF; Zilberberg MD; Wang L; Baser O; Yu H
Infect Control Hosp Epidemiol; 2016 Nov; 37(11):1331-1336. PubMed ID: 27572289
[TBL] [Abstract][Full Text] [Related]
78. Investigational Treatment Agents for Recurrent
Kullar R; Tran MN; Goldstein EJC
J Exp Pharmacol; 2020; 12():371-384. PubMed ID: 33116952
[No Abstract] [Full Text] [Related]
79. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.
Aitken SL; Joseph TB; Shah DN; Lasco TM; Palmer HR; DuPont HL; Xie Y; Garey KW
PLoS One; 2014; 9(7):e102848. PubMed ID: 25057871
[TBL] [Abstract][Full Text] [Related]
80. The outcomes of Clostridioides difficile infection in inpatient liver transplant population.
Amjad W; Qureshi W; Malik A; Singh R; Jafri SM
Transpl Infect Dis; 2022 Feb; 24(1):e13750. PubMed ID: 34695277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
